Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50line pembrolizumab.

Alex Friedlaender, Giulio Metro, Diego Signorelli, Alessio Gili, Panagiota Economopoulou, Fausto Roila, Giuseppe Banna, Alessandro De Toma, Andrea Camerini, Athina Christopoulou, Giuseppe Lo Russo, Marco Banini, Domenico Galetta, Beatriz Jimenez, Ana Collazo-Lorduy, Antonio Calles, Panagiotis Baxevanos, Helena Linardou, Paris Kosmidis, Giannis MountziosMarina C. Garassino, Alfredo Addeo

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50line pembrolizumab.'. Together they form a unique fingerprint.

Medicine & Life Sciences